# Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma

> **NCT01467986** · PHASE2 · COMPLETED · sponsor: **University of Regensburg** · enrollment: 130 (actual)

## Conditions studied

- Neuroblastoma Recurrent

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** Rapamycin
- **DRUG:** Irinotecan
- **DRUG:** Temozolomide
- **DRUG:** Irinotecan
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT01467986
- **Lead sponsor:** University of Regensburg
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2020-09-30
- **Final completion:** 2020-09-30
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2020-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01467986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01467986, "Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01467986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*